Stockpolly
Search
Delisting risk
PTN · NASDAQ · Biotechnology

Palatin Technologies (PTN)

Develops melanocortin agonists for rare obesity disorders through a partner-led pipeline.

$13.08
At close+1.57 (+13.64%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY23Jun 2023Q1 FY24Sep 2023Q2 FY24Dec 2023Q3 FY24Mar 2024Q4 FY24Jun 2024Q1 FY25Sep 2024Q2 FY25Dec 2024Q3 FY25Mar 2025Q4 FY25Jun 2025Q1 FY26Sep 2025Q2 FY26Dec 2025Q3 FY26Mar 2026
Revenue222000000904
Cost of revenue000000340000
Gross profit122000−3−40904
1288998−112476
Research & development756756342344
533242213232
General & administrative000000210032
Other expenses000000−6−4−2000
Operating income−11−6−7−9−8−8−3−5−25−7−2
11−1100000000
Interest income000000000000
Interest expense0000000000—0
Other non-operating income−1−11−100000000
Income before tax−10−5−8−8−8−8−2−5−25−7−1
Net income from continuing operations−10−5−8−8−8−8−2−5−25−7−1
Net income−10−5−8−8−8−8−2−5−25−7−1
EPS, basic−$0.84−$0.43−$0.56−$0.53−$0.56−$1.03−$0.32−$0.63−$0.52$4.81−$7.48−$1.47
EPS, diluted−$0.84−$0.43−$0.56−$0.53−$0.56−$1.03−$0.32−$0.63−$0.51$4.26−$6.61−$1.30
Weighted average shares, basic12121416158884111
Weighted average shares, diluted12121416158884111
EBITDA−10−5−8−8−8−8−2−5−25−7−1
Depreciation & amortization000000000000
EBIT−10−5−8−8−8−8−2−5−25−7−1